Yung Zip Chemical Ind. Co., Ltd.

TPEX:4102 Stock Report

Market Cap: NT$1.3b

Yung Zip Chemical Ind Past Earnings Performance

Past criteria checks 4/6

Yung Zip Chemical Ind has been growing earnings at an average annual rate of 29.2%, while the Pharmaceuticals industry saw earnings growing at 8.2% annually. Revenues have been growing at an average rate of 8.5% per year. Yung Zip Chemical Ind's return on equity is 12.2%, and it has net margins of 13.7%.

Key information

29.2%

Earnings growth rate

29.2%

EPS growth rate

Pharmaceuticals Industry Growth18.5%
Revenue growth rate8.5%
Return on equity12.2%
Net Margin13.7%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Yung Zip Chemical Ind (GTSM:4102) Seems To Use Debt Quite Sensibly

Apr 29
Yung Zip Chemical Ind (GTSM:4102) Seems To Use Debt Quite Sensibly

Yung Zip Chemical Ind. Co., Ltd.'s (GTSM:4102) Has Had A Decent Run On The Stock market: Are Fundamentals In The Driver's Seat?

Mar 04
Yung Zip Chemical Ind. Co., Ltd.'s (GTSM:4102) Has Had A Decent Run On The Stock market: Are Fundamentals In The Driver's Seat?

Yung Zip Chemical Ind (GTSM:4102) Seems To Use Debt Quite Sensibly

Jan 28
Yung Zip Chemical Ind (GTSM:4102) Seems To Use Debt Quite Sensibly

Are Yung Zip Chemical Ind's (GTSM:4102) Statutory Earnings A Good Guide To Its Underlying Profitability?

Dec 22
Are Yung Zip Chemical Ind's (GTSM:4102) Statutory Earnings A Good Guide To Its Underlying Profitability?

Should Weakness in Yung Zip Chemical Ind. Co., Ltd.'s (GTSM:4102) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Nov 25
Should Weakness in Yung Zip Chemical Ind. Co., Ltd.'s (GTSM:4102) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Revenue & Expenses Breakdown

How Yung Zip Chemical Ind makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

TPEX:4102 Revenue, expenses and earnings (TWD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24631868733
30 Jun 24611928533
31 Mar 24574728534
31 Dec 23559638434
30 Sep 23588678435
30 Jun 23577598335
31 Mar 23595838335
31 Dec 22567708135
30 Sep 22533517533
30 Jun 22496357132
31 Mar 22478146732
31 Dec 2147866631
30 Sep 21460126933
30 Jun 21483137135
31 Mar 21466107434
31 Dec 20463317333
30 Sep 20439307133
30 Jun 20427396831
31 Mar 20419426531
31 Dec 19417316431
30 Sep 19429266229
30 Jun 19422166028
31 Mar 19389-25827
31 Dec 18357-155626
30 Sep 18324-125726
30 Jun 18311-115625
31 Mar 18312-185824
31 Dec 17314-255924
30 Sep 17301-385422
30 Jun 17279-645422
31 Mar 17280-695123
31 Dec 16268-685022
30 Sep 16285-635224
30 Jun 16306-285225
31 Mar 16312-205228
31 Dec 15318-285428
30 Sep 15307-385328
30 Jun 15299-505327
31 Mar 15285-625325
31 Dec 14277-665225
30 Sep 14285-655327
30 Jun 14278-1025328
31 Mar 14278-875428
31 Dec 13300-675531

Quality Earnings: 4102 has high quality earnings.

Growing Profit Margin: 4102's current net profit margins (13.7%) are higher than last year (11.4%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 4102 has become profitable over the past 5 years, growing earnings by 29.2% per year.

Accelerating Growth: 4102's earnings growth over the past year (28.5%) is below its 5-year average (29.2% per year).

Earnings vs Industry: 4102 earnings growth over the past year (28.5%) exceeded the Pharmaceuticals industry 11.9%.


Return on Equity

High ROE: 4102's Return on Equity (12.2%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 12:51
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Yung Zip Chemical Ind. Co., Ltd. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Regina LeeIBTS Investment Consulting Co., Ltd.
Zhennan LeeJih Sun Securities Investment Consulting Co., Ltd.
Yuan LuKGI Securities Co. Ltd.